Why Partner with Us
Who We Are
Asahi Kasei Pharma Corporation is a research-based pharmaceutical company, headquartered in Tokyo, Japan, specializing in the therapeutic areas of pain management, musculoskeletal disorders, and critical care medicine.
Proven Record of Successful Partnerships
We have successfully partnered with large and small organizations to develop and commercialize a number of innovative treatments including Famvir® (famciclovir), Flivas™ (naftopidil), Toledomin™ (milnacipran hydrochloride), and Xiaflex® (collagenase clostridium histolyticum).
Commercial Access in Japan and East Asia
Asahi Kasei Pharma fields an experienced, nationwide sales force in Japan.
We have commercial access to other pharmaceutical markets in East Asia through our China subsidiary Asahi Kasei Pharma (Beijing) and partners in China, and partnerships in Korea and Taiwan.
Clinical Development/Regulatory Affairs Management in Japan, China, and Worldwide
We have a well-established record of managing clinical trials and successfully obtaining product marketing approvals in Japan.
We manage our clinical development activities and regulatory submissions in China through our subsidiary Asahi Kasei Pharma (Beijing).
We manage our global clinical development activities and regulatory submissions outside of Japan and China through our U.S. subsidiary Asahi Kasei Pharma America located near Boston, Massachusetts.
We discover and conduct preclinical testing of new drug compounds at our research campus near Tokyo, Japan, using proven drug discovery techniques and leading-edge technologies.